DXVX Partners with Youngjin Pharm for Innovative Drug Development

DXVX announced on the 5th that it has signed a strategic business agreement (MOU) with Youngjin Pharm for the development of innovative new drugs.

Through this business agreement, both companies plan to mutually cooperate in discovering new candidate substances in the field of innovative new drugs. In particular, by combining DXVX's AI-based drug design technology and clinical protocol expertise with Youngjin Pharm's synthesis and evaluation capabilities, they aim to accelerate the development of new treatments and maximize the success potential of new drug development.

Both companies have selected anticancer agents as the main target candidate substances and plan to expand the scope of new drug research and development (R&D) to various indications thereafter. Additionally, depending on the candidate substances secured and preclinical research results in the future, further joint research contracts are expected to follow.

Lee Ki-su, CEO of Youngjin Pharm, said, “We expect a great synergy to be created by combining Youngjin Pharm’s pharmaceutical development expertise with DXVX’s AI technology,” and added, “We will strengthen Youngjin Pharm’s R&D capabilities by discovering new candidate substances for innovative new drugs.” Kwon Kyu-chan, CEO of DXVX, stated, “Through this agreement, we plan to significantly reduce the time and cost required for new drug development by utilizing our AI technology, and since we can also provide Clidex companion diagnostic technology in the future, we aim to increase the success potential of new drugs,” adding, “We will strive to ensure that DXVX’s new drug development technology contributes to improving patients’ quality of life.”